Novel Anticancer Strategies (Volume II)

doi:10.3390/books978-3-0365-7032-7

Reprint

Download Flyer

Novel Anticancer Strategies (Volume II)

Edited by

March 2023

700 pages

ISBN978-3-0365-7033-4 (Hardback)
ISBN978-3-0365-7032-7 (PDF)

https://doi.org/10.3390/books978-3-0365-7032-7

Free download (PDF)

This book is a reprint of the Special Issue Novel Anticancer Strategies (Volume II) that was published in

Biology & Life Sciences

Chemistry & Materials Science

Medicine & Pharmacology

Summary

Novel Anticancer Strategies (Volume II) reviews important findings and updates within the cancer therapy field of great interest to those in academic research studying the development and validation of novel anticancer approaches. The Editor invited preeminent specialists to contribute to original and review articles devoted to key areas of major progress and expectations. Key Features:Nanoparticle-based drug delivery in cancer therapy;Nanoerythrosomes;Cancer immunotherapy;Therapeutic vaccines;Oncogenic and tumor suppressive components of the cell cycle;Antimitotics in cancer clinical trials;Multifunctional enzymes as anti-cancer drug targets;Targeting undruggable proteins and non-coding RNAs;Cell-penetrating peptides;Repurposed cancer drugs in clinical trials;Circulating tumour cells.

Format

Hardback

License

Keywords

Breast cancer treatment; Photodynamic therapy; Inorganic nanoparticles; Active targeting; cathepsins; BAX; MOMP; ubiquitination; apoptosis; chemotherapy; cancer; nanoerythrosome; nanoerythrocyte; nanovesicles; biomimetic; cancer therapy; diagnostics; imaging agents; cell cycle; cyclin-dependent kinase; p16; p21; p27; breast cancer; prognosis; drug delivery; HL60; leukemia; prodrug; resistance; retinoic acid; vitamin K; drug repurposing; COVID-19; cancer; pandemic; vaccination; cancer; multi-drug resistance; enhanced permeation and retention effect; nanotherapeutics; cancer theranostic; clinical translation; cell-penetrating peptides; protein transduction domains; tumor imaging; targeted therapies; dog; cancer; comparative oncology; molecular targets; spheroids; tumoroids; hydrogel; collagen; agarose; mammary spheroids; tissue engineering; breast cancer; cisplatin; cancer therapy; melanoma; melanin nanoparticles; cytotoxicity; laser medical applications; hyperthermia; cancer; antimitotics; mitotic slippage; spindle assembly checkpoint; clinical trials; TRAIL; cancer stem cells; TRAIL resistance; angiogenesis; on-demand drug delivery systems; electrospun nanofibers; poly (N-isopropylacrylamide); gold nanorods; paclitaxel; β-Cyclodextrin; SPIONs; breast cancer; metallodrugs; RAPTA derivatives; phosphino-amine ligands; CTCs; NSCLCs; metastasis suppression; curcumin; flavonoids; TNBC; immunotherapy; immune checkpoint; nanocarrier; drug delivery; combinational immunotherapy; lung cancer; angiogenesis; apoptosis; miRNA; oncomiRs; photodynamic therapy PDT; porphyrin; iron oxide nanoparticles; melanoma; mesoporous silica nanoparticles; antibody functionalization; targeted drug delivery systems; cancer; molecular-targeted therapies; multifunctional enzymes; HCC; CHRNA5; metastasis; stemness property; sorafenib sensitivity; cancer therapy; neoantigens; immunotherapy; vaccine; Patched; chemotherapy resistance; metastases; cancer stem cells; persistent cells; adrenocortical carcinoma; BUB3; spindle assembly checkpoint; mitosis; cancer; senescence; anticancer target; boron neutron capture therapy; 4-borono-l-phenylalanine; drug discovery; solubility; mebendazole; drug delivery; cancer therapy; polymer; HPMA; controlled drug release; PLK1; BI2536; Navitoclax; slippage; antimitotics; cancer therapy; mitosis; apoptosis; PD-1; nanovesicles; immunotherapy; gemcitabine; breast cancer; cancer therapy; new anti-cancer drugs; precision medicine; undruggable targets; non-coding RNAs; oligonucleotide therapeutics; n/a